Stockscreener 앱 받기
301.88
2.29%
-7.08
시장 영업 전:
302.98
1.10
+0.36%
전일 마감가:
$308.96
열려 있는:
$301.92
하루 거래량:
307.59K
Relative Volume:
1.21
시가총액:
$31.32B
수익:
$5.76B
순이익/손실:
$514.49M
주가수익비율:
67.36
EPS:
4.4813
순현금흐름:
$1.10B
1주 성능:
+3.83%
1개월 성능:
+11.48%
6개월 성능:
-5.77%
1년 성능:
+23.48%
1일 변동 폭
$299.06
$305.74
1주일 범위
$291.87
$316.00
52주 변동 폭
$249.00
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
명칭
Beone Medicines Ltd Adr
전화
41-616851900
주소
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
301.88 | 31.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.30 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Wolfe Research | Outperform |
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Barclays | Overweight |
| 2025-04-07 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-12-03 | 재개 | Morgan Stanley | Overweight |
| 2024-09-18 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-06 | 재개 | JP Morgan | Overweight |
| 2023-09-12 | 개시 | Macquarie | Outperform |
| 2023-08-17 | 개시 | Jefferies | Buy |
| 2023-07-17 | 개시 | Citigroup | Buy |
| 2023-06-30 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 개시 | Daiwa Securities | Buy |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-10-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 재개 | JP Morgan | Overweight |
| 2022-03-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 개시 | Deutsche Bank | Buy |
| 2021-10-12 | 개시 | Bernstein | Outperform |
| 2021-10-06 | 업그레이드 | CLSA | Underperform → Buy |
| 2021-03-08 | 개시 | China Renaissance | Buy |
| 2021-03-01 | 다운그레이드 | CLSA | Outperform → Underperform |
| 2020-11-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-06 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
모두보기
Beone Medicines Ltd Adr 주식(ONC)의 최신 뉴스
ONCBeOne Medicines Ltd ADR Options - Finviz
BeOne Medicines Ltd.American Depositary Shares (ONC) Stock Price, News, Quote & History - FinancialContent
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy - Sahm
49BA Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
A1437N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
Price to book forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
Enterprise value to revenue forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ONC) - TradingView
BeOne Medicines Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
Price to sales forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 3,410 Shares - MarketBeat
Price to book forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
Enterprise value to EBITDA forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
Temasek Holdings Private Ltd Sells 91,877 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Barings LLC Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Here's How Much You Would Have Made Owning BeOne Medicines Stock In The Last 10 Years - Sahm
A Look At BeOne Medicines (ONC) Valuation After Analyst Upgrades And Positive ASCO 2026 Clinical Updates - Sahm
Capital International Sarl Raises Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Is BeOne Medicines (ONC) Quietly Recasting Its Hematology Roots Into a Multi-Franchise Oncology Platform? - Sahm
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 - sharewise.com
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Range Breakout - AASTOCKS.com
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Triangle Breakout - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 5.1M shares at $176.8, $901.68M turnover - AASTOCKS.com
BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 254.9K shares at $175.1, $44.633M turnover - AASTOCKS.com
CICC: Focus on Positive Capital Flow Impact from Index Review on BEONE MEDICINES (06160.HK), J&T EXPRESS-W (01519.HK), KNOWLEDGE ATLAS (02513.HK) and MINIMAX-W (00100.HK) - AASTOCKS.com
Marriott Upgraded, Roku Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Bearish block trade of BEONE MEDICINES(06160) 231.3K shares at $185.8, $42.976M turnover - AASTOCKS.com
BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative - Sahm
HSI To Add J&T EXPRESS-W (01519.HK), CHALCO (02600.HK), BEONE MEDICINES (06160.HK) after Quarterly Review - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 212K shares at $184.5, $39.114M turnover - AASTOCKS.com
ONC Stock Price, Quote & Chart | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Ltd.: BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - FinanzNachrichten.de
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - Via TT
Bearish block trade of BEONE MEDICINES(06160) 323.6K shares at $183.1, $59.251M turnover - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 206.1K shares at $175.1, $36.088M turnover - AASTOCKS.com
BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer - Sahm
BeiGene Must Face AbbVie's Chemical Trade Secret Claims - Law360
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - ChartMill
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Apple Upgraded, American Express Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BeOne Medicines (ONC) Is Up 7.4% After Guidance Hike And Priority Review Win In HER2 Cancer - Sahm
Citi Raises BeOne Medicines Ltd. (ONC.US) TP to USD453; 1Q26 Results Strong - AASTOCKS.com
Sigma Planning Corp Sells 3,208 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Earnings Beat: BeOne Medicines AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
UBS Group AG Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Beone Medicines Ltd Adr (ONC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
7.48%
0.99%
자본화:
|
볼륨(24시간):